$11.36
+0.13 (+1.16%)
Open$11.06
Previous Close$11.23
Day High$11.60
Day Low$11.06
52W High$18.17
52W Low$8.48
Volume—
Avg Volume8.3K
Market Cap54.80M
P/E Ratio—
EPS$-2.84
SectorBiotechnology
Analyst Ratings
Strong Buy
8 analysts
Price Target
+75.8% upside
Current
$11.36
$11.36
Target
$19.97
$19.97
$17.96
$19.97 avg
$26.10
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 45.10M | 46.49M | 39.49M |
| Net Income | 3.70M | 3.34M | 2.56M |
| Profit Margin | 8.2% | 7.2% | 6.5% |
| EBITDA | 5.80M | 5.78M | 5.15M |
| Free Cash Flow | 3.02M | 2.12M | 2.20M |
| Rev Growth | +4.3% | +20.2% | +6.0% |
| Debt/Equity | 0.88 | 1.05 | 1.14 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $249.46 | -0.54% | 70.2 | 443.23B |
| AMGN | Amgen Inc | $415.21 | -0.63% | 25.8 | 225.90B |
| GILD | Gilead Sciences Inc | $138.36 | +0.16% | — | 169.87B |
| VRTX | Vertex Pharmaceuticals Inc | $505.75 | -2.07% | 30.7 | 135.24B |
| REGN | Regeneron Pharmaceuticals | $803.48 | -0.31% | 19.0 | 82.16B |
| ALNY | Alnylam Pharmaceuticals Inc | $228.65 | +0.67% | 37.6 | 30.39B |